Canada's DiagnoCure Inc said it received U.S. regulatory approval for a prostate cancer test that may help avoid unnecessary biopsies, sending its shares to their highest in about 18 months.
The urine-based test -- named Progensa PCA3 -- will be used with other patient information to help decide on repeat biopsy in men of 50 years or older.
The company said the PCA3 test will now be available for sale in the United States, Canada and the European Union.
Read the full Reuters report:
DiagnoCure gets FDA nod for prostate cancer test, shares jump
